21f65654-07a2-4b27-b511-2497fa298d0e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 65.5030800821355
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- INTERFERON_ALPHA_RESPONSE+0.440
- MYC_TARGETS_V1+0.400
- OXIDATIVE_PHOSPHORYLATION+0.370
- COAGULATION+0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- INTERFERON_GAMMA_RESPONSE+0.340
- IL6_JAK_STAT3_SIGNALING+0.260
- UV_RESPONSE_UP+0.260
- ALLOGRAFT_REJECTION+0.230
Top 10 suppressed
- MITOTIC_SPINDLE-0.350
- G2M_CHECKPOINT-0.270
- UV_RESPONSE_DN-0.250
- CHOLESTEROL_HOMEOSTASIS-0.200
- HEDGEHOG_SIGNALING-0.190
- HEME_METABOLISM-0.180
- KRAS_SIGNALING_DN-0.160
- E2F_TARGETS-0.140
- ANDROGEN_RESPONSE-0.120
- PROTEIN_SECRETION-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | cddceb59-733b-48d1-9b75-46c9949f7794 | — | — | 0.780 |
| 2 | MNG1091 | — | — | 0.771 |
| 3 | TCGA-CV-A6JD-01A-11R-A31N-07 | — | — | 0.741 |
| 4 | C884FB38-DE5C-48BA-95F1-4ABD2991E833 | — | — | 0.739 |
| 5 | TCGA-64-5781-01A-01R-1628-07 | — | cohortA4 | 0.725 |
| 6 | MNG1097 | — | — | 0.721 |
| 7 | MNG478 | — | — | 0.717 |
| 8 | 65DAB913-D39C-4AC4-BB1C-10E58914571F | — | — | 0.715 |
| 9 | MNG302 | — | — | 0.713 |
| 10 | TCGA-D8-A1Y2-01A-11R-A157-07 | — | C | 0.712 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.130 | Idelalisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |